Table 4.
Characteristics of patients with and without post‐progression therapy at the first‐line tyrosine kinase inhibitor therapy
| With post‐progression therapy | Without post‐progression therapy | P‐value | |
|---|---|---|---|
| N | 226 | 287 | |
| Age (years) | 70.2 ± 8.9 | 69.8 ± 10.9 | NS |
| Sex (male/female) | 192/34 | 232/55 | NS |
| BMI (kg/m2) | 23.4 ± 3.7 | 23.4 ± 5.6 | NS |
| Etiology (viral/non‐viral) | 136/90 | 169/118 | NS |
| Complication: hypertension | 131 (58%) | 149 (52%) | NS |
| Complication: diabetes | 63 (28%) | 92 (32%) | NS |
| AFP (ng/mL) (>400) | 73 (32%) | 108 (38%) | NS |
| DCP (mAU/mL) (>400) | 117 (52%) | 175 (50%) | NS |
| APRI | 1.05 ± 0.97 | 1.17 ± 1.04 | 0.031 |
| FIB‐4 index | 4.97 ± 0.27 | 4.92 ± 0.32 | NS |
| ECOG PS (0/1/2) | 162/35/5 | 141/61/9 | <0.01 |
| Child–Pugh score | 5.83 ± 1.09 | 6.29 ± 1.35 | <0.01 |
| ALBI grade (1/2/3) | 87/132/7 | 65/160/17 | <0.01 |
| ALBI score | −2.38 ± 0.47 | −2.23 ± 0.53 | <0.01 |
| TNM stage (2/3/4) | 25/69/116 | 30/63/134 | NS |
| Within Up‐to‐7 criteria | 94 (42%) | 99 (34%) | NS |
| Treatment duration (days) (median) | 118 (1–1932) | 104 (1–1914) | NS |
| Grade ≥ 2 AEs | 131 (58%) | 119 (41%) | NS |
| Therapy after first line, TACE | 76 (34%) | ||
| Radiation therapy | 23 (10%) | ||
| Second line TKIs | 85 (38%) | ||
| ICI | 50 (22%) | ||
| Operation | 4 (1.8%) | ||
| Radiofrequency ablation | 3 (1.3%) |
Values are n, n (%), or mean ± SD, unless otherwise specified.
AE, adverse event; AFP, alpha‐fetoprotein; ALBI, albumin‐bilirubin; APRI, AST to platelet ratio index; BMI, body mass index; DCP, des‐gamma‐carboxy pro‐ thrombin; ECOG PS; Eastern Cooperative Oncology Group performance status; FIB‐4, fibrosis‐4; ICI, immune checkpoint inhibitor; NS, not significant; TACE, transarterial chemoembolization; TKI, tyrosine kinase inhibitor; TNM, tumor‐node‐metastasis.